# A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

> **NCT04547101** · PHASE2 · TERMINATED · sponsor: **Akeso** · enrollment: 6 (actual)

## Conditions studied

- MSI-H/dMMR Solid Tumor

## Interventions

- **DRUG:** AK104

## Key facts

- **NCT ID:** NCT04547101
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-24
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop study.
- **Last updated:** 2022-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04547101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04547101, "A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04547101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*